[HTML][HTML] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard, MK Connolly… - Respiratory …, 2008 - Elsevier
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
[PDF][PDF] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard, MK Connolly… - Respiratory …, 2008 - core.ac.uk
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
[HTML][HTML] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard… - Respiratory …, 2008 - resmedjournal.com
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
[引用][C] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC ZAMORA, PJ WOLTERS… - Respiratory …, 2008 - pascal-francis.inist.fr
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[PDF][PDF] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard… - Respiratory …, 2008 - academia.edu
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
AC Zamora, PJ Wolters, HR Collard… - Respiratory …, 2007 - europepmc.org
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
[引用][C] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard, MK Connolly… - Respiratory …, 2008 - cir.nii.ac.jp
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard, MK Connolly… - Respiratory …, 2008 - infona.pl
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard… - Respiratory …, 2008 - pubmed.ncbi.nlm.nih.gov
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
[PDF][PDF] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
AC Zamora, PJ Wolters, HR Collard… - Respiratory …, 2008 - academia.edu
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …